Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.
Erika J LampertAlexandra S ZimmerMichelle PadgetAshley Cimino-MathewsJayakumar R NairYingmiao LiuElizabeth M SwisherJames W HodgeAndrew B NixonErin NicholsMohammad Hadi BagheriElliott LevyMarc R RadkeStanley LipkowitzChristina M AnnunziataJanis M TaubeSeth M SteinbergJung-Min LeePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
The PARPi and anti-PD-L1 combination showed modest clinical activity in recurrent ovarian cancer. Our correlative study results suggest immunomodulatory effects by olaparib/durvalumab in patients and indicate that VEGF/VEGFR pathway blockade would be necessary for improved efficacy of the combination.